KEAP1 and non-small cell lung carcinoma: Results from two multicenter randomized clinical trials showed that advanced NSCLC patients with KEAP1/NFE2L2 mutations had worse clinical outcomes than wild-type patients when treated with immunotherapy and chemotherapy (30).